Common Contracts

2,857,143 Shares ACHIEVE LIFE SCIENCES, INC. Common Stock UNDERWRITING AGREEMENT

Underwriting Agreement • May 25th, 2021 • Achieve Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York

• Contract Type
  Underwriting Agreement
• Filed
  May 25th, 2021
• Company
  Achieve Life Sciences, Inc.
• Industry
  In vitro & in vivo diagnostic substances
• Jurisdiction
  New York

Achieve Life Sciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 2,857,143 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 428,571 shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”

OUTLOOK THERAPEUTICS, INC. [●] Shares of Common Stock UNDERWRITING AGREEMENT

Underwriting Agreement • April 2nd, 2019 • Outlook Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

• Contract Type
  Underwriting Agreement
• Filed
  April 2nd, 2019
• Company
  Outlook Therapeutics, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained in this Underwriting Agreement (the “Agreement”), to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of [●] shares (the “Firm Shares”) of the Company’s common stock, $0.01 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional [●] shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”